
FEXUPRAZAN HCL
Price | Get Latest Price | |
Package | 1g | 10g |
Min. Order: | 1g |
Supply Ability: | 5kg |
Update Time: | 2025-03-04 |
Product Details
Product Name: FEXUPRAZAN HCL | CAS No.: 1902954-87-3 |
Min. Order: 1g | Purity: 0.99 |
Supply Ability: 5kg | Release date: 2025/03/04 |
? ?Fexuprazan Hydrochloride (CAS 1902954-87-3) | High-Purity Potassium-Competitive Acid Blocker (P-CAB)? ?
?? ?Product Overview?
?Fexuprazan Hydrochloride? (CAS 1902954-87-3), also known as ?Abeprazan HCl?, is a potent ?potassium-competitive acid blocker? (P-CAB) with the molecular formula ?C??H??ClF?N?O?S? and a molecular weight of ?446.87?. This white to light-yellow crystalline powder (purity ≥98%) is designed for ?acid-related gastrointestinal disorder treatment?, offering rapid and sustained suppression of gastric acid secretion. It acts by inhibiting H+/K+-ATPase in gastric parietal cells, making it a superior alternative to traditional proton pump inhibitors (PPIs) with faster onset and longer duration.
?Key Functions?:
Treats gastroesophageal reflux disease (GERD) and peptic ulcers.
Enhances Helicobacter pylori eradication therapy efficacy.
Serves as a pharmaceutical intermediate for advanced formulations.
?Target Industries?: Pharmaceutical manufacturing, clinical research, and biotechnology.
? ?Key Advantages?
≥98% HPLC/EP-certified | 1g to 25kg bulk options | Stable at -20°C, moisture-proof |
Batch-specific COA | Tamper-evident packaging | 24-month shelf life |
?? ?Applications?
?GERD Management?: Oral tablets or capsules for chronic acid reflux relief.
?Peptic Ulcer Therapy?: Combined with antibiotics for H. pylori eradication.
?Drug Development?: Intermediate for novel P-CAB formulations and bioavailability studies.
?? ?Quality Assurance?
?Testing Standards?: Complies with ?USP/EP? pharmacopeial guidelines.
?Analytical Validation?: HPLC, NMR, and LC-MS for identity and impurity profiling.
?Certifications?: ISO 9001 and GMP compliance for pharmaceutical-grade production.
?? ?Market Insights?
The global GERD treatment market is projected to reach ?$6.8 billion by 2030?, driven by rising prevalence of acid-related disorders and demand for non-PPI therapies. Fexuprazan is gaining traction in ?Asia-Pacific? due to cost-effective manufacturing and expanding healthcare infrastructure.
Company Profile Introduction
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$400.00/1kg |
VIP1Y
|
Hebei Junhua Import and Export Co., LTD
|
2025-02-19 | |
$94.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-01 | |
$94.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-01 |
- Since: 2018-06-08
- Address: Biolake.858 high-tech avenue,Wuhan
+86-+undefined-+86 13343427080
sales@biocarchem.com